FDA approves Erbitux to treat late-stage head and neck cancer
The U.S. Food and Drug Administration today approved Erbitux ( cetuximab ) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.
Radiant News about Head and Neck Cancer
For advanced head and neck cancers that have stopped responding to other therapies, there may be a new treatment option that uses something you leaned about in high school science class.
Gene Expression and Metastasis in Head and Neck Cancer
A study of 222 cases of oral or oropharyngeal cancer has yielded startling results about the role of gene expression in metastasis.